Lead Interdisciplinary Scientist / Pharmacologist US FDA
Regulatory aspects of peptide development will be discussed based on the experience of FDA, CDER, providing insight on how the differences in the definition of a biologic peptide compared with a small molecule peptide impacts the toxicology program design for FDA submission. Common acceptable deviations from standard guidance documents based on scientific rationale will be discussed.
